ReviewThe Korean journal of internal medicine2023
Sarcopenia in chronic kidney disease: from bench to bedside.
Review in The Korean journal of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- [Effect of the Otago Exercise Program on Activities of Daily Living in Older Adults With Sarcopenia].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Trial
- Muscle Strength Profiles According to Kidney Dysfunction and Anemia Status in Korean Adults Aged ≥40 Years: A Nationwide Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Finger-Ring Test and Low Muscle Mass in Older Adults with Chronic Kidney Disease: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Sarcopenic obesity and body composition phenotypes in older adults with chronic kidney disease: associations with estimated mortality risk.Scientific reports · 2026Article
- Efficacy of Transcatheter Renal Arterial Embolization to Contract Renal Size and Increase Muscle Mass in Patients with Polycystic Kidney Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Bidirectional association between sarcopenia and diabetic kidney disease: a prospective cohort study.BMC nephrology · 2026Article
- Research trends and potential molecular intersections between diabetic kidney disease and sarcopenia: a 21-year bibliometric and bioinformatics analysis.Frontiers in endocrinology · 2026Review
- Type 2 Diabetes and Hemodialysis: Metabolic Challenges and the Role of Intradialytic Exercise.Clinical medicine insights. Endocrinology and diabetes · 2026Review
- Shared decision-making for kidney replacement therapy: a comprehensive review and a proposed model.The Korean journal of internal medicine · 2025Review
- Clinical benefits and future directions of medium cut-off membranes in hemodialysis: a comprehensive review.The Korean journal of internal medicine · 2025Review
- Sarcopenia in Peritoneal Dialysis: Prevalence, Pathophysiology, and Management Strategies.Kidney medicine · 2025Review
- In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.Cancers · 2025Review
- Review
- Health-related quality of life and its predictors among chronic kidney disease patients: A hospital-based cross-sectional study.PloS one · 2025Article
- Article
- Steps to understanding diabetes kidney disease: a focus on metabolomics.The Korean journal of internal medicine · 2024Review
- Dietary inflammatory index could increase the risk of sarcopenia in patients with chronic kidney disease.Scientific reports · 2024Article
- Skeletal Muscle Injury in Chronic Kidney Disease-From Histologic Changes to Molecular Mechanisms and to Novel Therapies.International journal of molecular sciences · 2024Review
- The Potential Influence of Uremic Toxins on the Homeostasis of Bones and Muscles in Chronic Kidney Disease.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a condition characterized by a loss of muscle mass and function. In chronic kidney disease (CKD), where a chronic catabolic state exists, sarcopenia commonly occurs through various mechanisms, resulting in muscle wasting and decreased muscle endurance. Sarcopenic patients with CKD have high morbidity and mortality rates. Indeed, the prevention and treatment of sarcopenia are mandatory. An imbalance between protein synthesis and degradation in muscle and increased oxidative stress and inflammation persist in CKD and induce muscle wasting. In addition, uremic toxins negatively affect muscle maintenance. A variety of potential therapeutic drugs targeting these muscle-wasting mechanisms in CKD have been investigated, but most of the trials focused on aged patients without CKD, and none of these drugs have been approved for the treatment of sarcopenia so far. Further studies on the molecular mechanisms of sarcopenia in CKD and targets for potential therapeutics are needed to improve the outcomes of sarcopenic patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.